A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal Adenomas

Gastroenterology

Volumn 131, Issue 6, 2006, Pages 1674-1682

  Baron, John A ^a   Sandler, Robert S ^b   Bresalier, Robert S ^g   Quan, Hui ^c   Riddell, Robert ^d   Lanas, Angel ^f   Bolognese, James A ^c   Oxenius, Bettina ^c   Horgan, Kevin ^c   Loftus, Susan ^c   Morton, Dion G ^e  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d MOUNT SINAI HOSPITAL   (Canada)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^g UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANTIPYRETIC AGENT; CELECOXIB; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

ADULT; ARTICLE; CANCER RISK; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLONOSCOPY; COLORECTAL ADENOMA; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM PERFORATION; DIGESTIVE SYSTEM ULCER; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENZYME INHIBITION; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NUTRITIONAL DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; THROMBOSIS; TREATMENT OUTCOME; TUMOR RECURRENCE; URINARY TRACT DISEASE;

EID: 33845288081     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.gastro.2006.08.079     Document Type: Article

References (28)

1. Baron J.A. Epidemiology of non-steroidal anti-inflammatory drugs and cancer. Prog Exp Tumor Res 37 (2003) 1-24
2. Thun M.J., Henley S.J., and Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94 (2002) 252-266
3. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
4. Reddy B.S., Rao C.V., Rivenson A., and Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 14 (1993) 1493-1497
5. Higuchi T., Iwama T., Yoshinaga K., Toyooka M., Taketo M.M., and Sugihara K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin Cancer Res 9 (2003) 4756-4760
6. Steinbach G., Lynch P.M., Phillips R.K., Wallace M.H., Hawk E., Gordon G.B., Wakabayashi N., Saunders B., Shen Y., Fujimura T., Su L.K., and Levin B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 342 (2000) 1946-1952
7. Baron J.A., Cole B.F., Sandler R.S., Haile R.W., Ahnen D., Bresalier R., McKeown-Eyssen G., Summers R.W., Rothstein R., Burke C.A., Snover D.C., Church T.R., Allen J.I., Beach M., Beck G.J., Bond J.H., Byers T., Greenberg E.R., Mandel J.S., Marcon N., Mott L.A., Pearson L., Saibil F., and van Stolk R.U. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 348 (2003) 891-899
8. Sandler R.S., Halabi S., Baron J.A., Budinger S., Paskett E., Keresztes R., Petrelli N., Pipas J.M., Karp D.D., Loprinzi C.L., Steinbach G., and Schilsky R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. [erratum appears in N Engl J Med 2003;348:1939.]. ] N Engl J Med 348 (2003) 883-890
9. Vane J.R. Biomedicine. Back to an aspirin a day?. Science 296 (2002) 474-475
10. Marnett L.J., and DuBois R.N. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42 (2002) 55-80
11. Silverstein F.E., Faich G., Goldstein J.L., Simon L.S., Pincus T., Whelton A., Makuch R., Eisen G., Agrawal N.M., Stenson W.F., Burr A.M., Zhao W.W., Kent J.D., Lefkowith J.B., Verburg K.M., and Geis G.S. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284 (2000) 1247-1255
12. Bombardier C., Laine L., Reicin A., Shapiro D., Burgos-Vargas R., Davis B., Day R., Ferraz M.B., Hawkey C.J., Hochberg M.C., Kvien T.K., Schnitzer T.J., Group V.S., and VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343 (2000) 1520-1528
13. Sandler R.S. Epidemiology and risk factors for colorectal cancer. Gastroenterol Clin North Am 25 (1996) 717-735
14. Baron J., Beach M., Mandel J., Van Stolk R., Haile R., Sandler R., Rothstein R., Summers M., Snover D., Beck G., Bond J., and Greenberg E. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 340 (1999) 101-107
15. Agresti A. An introduction to categorical data analysis (1996), Wiley, New York, NY
16. Bresalier R.S., Sandler R.S., Quan H., Bolognese J.A., Oxenius B., Horgan K., Lines C., Riddell R., Morton D., Lanas A., Konstam M.A., and Baron J.A. Adenomatous polyp prevention on Vioxx trial I. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 352 (2005) 1092-1102
17. Baron J.A., Sandler R.S., Bresalier R.S., Quan H., Riddell R., Lanas A., Bolognese J.A., Oxenius B., Horgan K., Loftus S., and Morton D.G. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 131 (2006) 1674-1682
18. Giardiello F.M., Hamilton S.R., Krush A.J., Piantadosi S., Hylind L.M., Celano P., Booker S.V., Robinson C.R., and Offerhaus G.J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 328 (1993) 1313-1316
19. Dannenberg A.J., Altorki N.K., Boyle J.O., Dang C., Howe L.R., Weksler B.B., and Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol 2 (2001) 544-551
20. Shiff S.J., and Rigas B. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs). J Exp Med 190 (1999) 445-450
21. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90 (1998) 1529-1536
22. Rex D.K., Cutler C.S., Lemmel G.T., Rahmani E.Y., Clark D.W., Helper D.J., Lehman G.A., and Mark D.G. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 112 (1997) 24-28
23. Hixson L.J., Fennerty M.B., Sampliner R.E., McGee D., and Garewal H. Prospective study of the frequency and size distribution of polyps missed by colonoscopy. J Natl Cancer Inst 82 (1990) 1769-1772
24. Bertagnolli M.M., Eagle C.J., Zauber A.G., Redston M., Solomon S.D., Kim K., Tang J., Rosenstein R.B., Wittes J., Corle D., Hess T.M., Woloj G.M., Boisserie F., Anderson W.F., Viner J.L., Bagheri D., Burn J., Chung D.C., Dewar T., Foley T.R., Hoffman N., Macrae F., Pruitt R.E., Saltzman J.R., Salzberg B., Sylwestrowicz T., Gordon G.B., Hawk E.T., and APC Study Investigators. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355 (2006) 873-884
25. Arber N., Eagle C.J., Spicak J., Racz I., Dite P., Hajer J., Zavoral M., Lechuga M.J., Gerletti P., Tang J., Rosenstein R.B., Macdonald K., Bhadra P., Fowler R., Wittes J., Zauber A.G., Solomon S.D., Levin B., and PreSAP Trial Investigators. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355 (2006) 885-895
26. U.S. Food and Drug Administration. Analysis and recommendations for agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. 2005.
27. Loeve F., van Ballegooijen M., Snel P., and Habbema J.D. Colorectal cancer risk after colonoscopic polypectomy: a population-based study and literature search. Eur J Cancer 41 (2005) 416-422
28. Robertson D.J., Greenberg E.R., Beach M., Sandler R.S., Ahnen D., Haile R.W., Burke C.A., Snover D.C., Bresalier R.S., McKeown-Eyssen G., Mandel J.S., Bond J.H., Van Stolk R.U., Summers R.W., Rothstein R., Church T.R., Cole B.F., Byers T., Mott L., and Baron J.A. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 129 (2005) 34-41